Assembly Biosciences (ASMB) Cash from Operations (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Cash from Operations of 22097000.0 for Q1 2026, up 5.73% year-over-year from 20900350.39 in Q1 2025, and down 255.21% quarter-over-quarter from 14237000.0 in Q4 2025.
Assembly Biosciences (ASMB) Cash from Operations (2010 - 2026) Analysis & Trends
Assembly Biosciences' Cash from Operations history runs 17 years deep, the most recent figure standing at 22097000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 5.73% year-over-year to 22097000.0; the TTM figure through Mar 2026 stood at 39751000.0 (up 29.26% YoY), while the FY2025 annual figure was 41093000.0, up 19.61% from the prior year.
- Cash from Operations for Q1 2026 stood at 22097000.0, down from 14237000.0 in the prior quarter.
- The five-year high for Cash from Operations was 73647000.0 in Q4 2023, with the low at 27502000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 17102000.0 (2024), against an average of 10354529.41.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 100.55% in 2024, then jumped 3598.03% in 2025.
- Assembly Biosciences' Cash from Operations stood at 19254000.0 in 2022, then jumped by 482.5% to 73647000.0 in 2023, then tumbled by 100.55% to 407000.0 in 2024, then surged by 3598.03% to 14237000.0 in 2025, then sank by 255.21% to 22097000.0 in 2026.
- Business Quant data shows ASMB's Cash from Operations at 22097000.0 in Q1 2026, 14237000.0 in Q4 2025, and 15133000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -15.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.49 Mn |
| Jun 30, 2026 | -15.49 Mn |
| Mar 31, 2026 | -22.10 Mn |
| Mar 31, 2026 | -22.10 Mn |
| Dec 31, 2025 | 14.24 Mn |
| Dec 31, 2025 | 14.24 Mn |
| Sep 30, 2025 | -15.13 Mn |
| Sep 30, 2025 | -15.13 Mn |
| Jun 30, 2025 | -16.76 Mn |
| Jun 30, 2025 | -16.76 Mn |
| Mar 31, 2025 | -23.44 Mn |
| Mar 31, 2025 | -23.44 Mn |
| Dec 31, 2024 | -407,000.00 |
| Dec 31, 2024 | -407,000.00 |
| Sep 30, 2024 | -15.24 Mn |
| Sep 30, 2024 | -15.24 Mn |
| Jun 30, 2024 | -17.10 Mn |
| Jun 30, 2024 | -17.10 Mn |
| Mar 31, 2024 | -18.36 Mn |
| Mar 31, 2024 | -18.36 Mn |